What is GLP-1 microdosing, and can smaller doses of medications like Ozempic, Wegovy, and Zepbound lead to better long-term weight loss results?

In this episode, registered dietitian Zoe is joined by Deidre, FNP, to break down one of the biggest conversations in obesity medicine right now: GLP-1 microdosing. They explain how microdosing differs from standard manufacturer dosing, why FDA-approved dosing schedules are designed for clinical trials, and why a one-size-fits-all approach may not work for every patient.

Deidre explains how slower, smaller dose increases may help reduce side effects like nausea and abdominal discomfort, while still supporting hunger control, fewer cravings, less food noise, and gradual weight loss. They also discuss super responders, non-responders, compounded medications, and why personalized GLP-1 dosing can make a major difference in long-term maintenance.

They also unpack the debate around GLP-1 microdose marketing, including the recent dispute involving Eli Lilly, Noom, and tirzepatide, and what it means for patients navigating telehealth weight loss programs.

Most importantly, Zoe and Deidre explain why medications are only one part of obesity treatment. Sustainable weight loss still depends on nutrition, whole foods, protein, fiber, lifestyle changes, and long-term support.